Eversens designs, develops, manufactures and markets innovative breath analysis solutions that provide clinicians with objective biomarker data. Its first product, evernoa, helps refine asthma diagnosis and therapy selection by measuring airway inflammation and has enabled more than 150,000 tests across 22 countries. Building on this traction, the company has created evernoa mini, a home-use and primary-care device that regularly monitors inflammation to identify patients at risk of asthma attacks. The firm is backed by a global, highly qualified team and leading respiratory KOLs. Eversens plans to expand into additional international markets, including the United States, and is preparing a Series A round to fund this growth. The company positions itself as a leader in breath biomarker analysis aimed at improving the quality of life for millions of respiratory patients worldwide.

Total raised

$190M

Funding rounds

6

Latest round

Equity

Latest activity

Jul 2020